Sociedad Americana de Hirudoterapia

Tissue factor/TFPI and blood cells.

Review published in Thrombosis research (2011)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosFarmacología salivalOsterud · Thrombosis research, 2011

Abstract

Vascular injury-induced access of blood to tissue factor (TF) leads to the formation of a TF-FVII/FVIIa complex and the triggering of blood coagulation. The activated TF-dependent pathway is regulated by Tissue Factor Pathway Inhibitor (TFPI), which binds and inhibits FXa, but more importantly forms an inactive quaternary complex with TF-FVIIa-FXa, effectively shutting off the TF activity. The old view of TF residing in extravascular sites exclusively has recently been challenged by several reports on TF expression in various blood cells. The latter arena has unfortunately been marred by many contradictions, apparently related to inferior tools and/or study design, notably the widespread use of antibodies with inferior and misleading specificity and TF activity assays of low sensitivity/specificity. Our own studies along with many other reports, compels the conclusion that in blood of healthy individuals TF is exclusively associated with and expressed in circulating monocytes. In this short review the distribution of TF and TFPI in blood is discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsBlood CellsBlood CoagulationBlood PlateletsCell-Derived MicroparticlesCoagulantsEosinophilsHemophilia AHumansLipoproteinsMonocytesNeutrophils

Resumen

Vascular injury-induced access of blood to tissue factor (TF) leads to the formation of a TF-FVII/FVIIa complex and the triggering of blood coagulation. The activated TF-dependent pathway is regulated by Tissue Factor Pathway Inhibitor (TFPI), which binds and inhibits FXa, but more importantly...

Por qué esto importa para la hirudoterapia

This review discussed the distribution of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in blood cells, concluding that in healthy individuals TF is exclusively associated with circulating monocytes while noting contradictions in prior literature due to inferior antibodies and assays. The relevance to ASH is peripheral — the abstract addresses coagulation initiation and regulation but involves no leeches, hirudin, or leech-derived molecules. Caveat: no leech involvement; indirect relevance as general coagulation biology context only.

Citación

Tissue factor/TFPI and blood cells.

Osterud · Thrombosis research, 2011

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.